<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620785</url>
  </required_header>
  <id_info>
    <org_study_id>0106171</org_study_id>
    <nct_id>NCT04620785</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Treatment of Verrucae</brief_title>
  <official_title>PHOTODYNAMIC THERAPY USING METHYLENE BLUE AND INTENSE PULSED LIGHT VERSUS INTENSE PULSED LIGHT ALONE IN TREATMENT OF VERRUCA :A RANDOMIZED CONTROLLED STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy (clinically and dermoscopically) and safety of photodynamic therapy&#xD;
      using intralesional injection of 4% methylene blue solution as a photosensitizer with IPL&#xD;
      versus IPL only in treatment of warts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted on:&#xD;
&#xD;
      Eighty patients suffering of verruca (male and female) divided randomly into three groups:&#xD;
      group A, B&amp;C :&#xD;
&#xD;
      Group A: 30 patients will undergo photodynamic therapy using intralesional 4%methylene blue&#xD;
      solution and IPL.&#xD;
&#xD;
      Group B: 30 patients will undergo IPL only. Group C (control group):20 patients will undergo&#xD;
      intralesional saline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disappearance of verruca</measure>
    <time_frame>10 weeks</time_frame>
    <description>clinical and dermoscopic cure</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Verruca Vulgaris</condition>
  <arm_group>
    <arm_group_label>methylene blue/IPL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will undergo photodynamic therapy using intralesional 4%methylene blue solution ,after a period of 15 minutes the patient will be subjected to IPL session.&#xD;
This will be repeated biweekly until complete clearance of the lesion or a maximum four sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will undergo biweekly IPL sessions only until complete clearance of the lesion or a maximum four sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will undergo intralesional saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>methylene blue / IPL</intervention_name>
    <description>therapeutic</description>
    <arm_group_label>methylene blue/IPL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IPL</intervention_name>
    <description>therapeutic</description>
    <arm_group_label>IPL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>placebo</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age:Above 16 years old.&#xD;
&#xD;
          2. Sex:Both males and female patients.&#xD;
&#xD;
          3. Clinically and dermoscopically documented verruca.&#xD;
&#xD;
          4. No verruca treatment in the last 2 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of photosensitivity disorder.&#xD;
&#xD;
          2. Pregnant and lactating females.&#xD;
&#xD;
          3. Diseases with risk of koebnerization e.g. Psoriasis and Lichen planus.&#xD;
&#xD;
          4. Anogenital warts.&#xD;
&#xD;
          5. Warts on head and neck.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alexandria University Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>amira abulfotooh eid, MD</last_name>
      <phone>01006897449</phone>
      <email>dramiraeid@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>marwa eldeeb</investigator_full_name>
    <investigator_title>lecturer of dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

